Startseite>>Signaling Pathways>> Obesity, Appetite Control & Diabetes>> Obesity>>P053

P053

Katalog-Nr.GC44529

P053 ist ein potenter, nicht kompetitiver und selektiver Inhibitor der Ceramidsynthase 1 (CerS1) mit einem IC50 von 0,5 μM.

Products are for research use only. Not for human use. We do not sell to patients.

P053 Chemische Struktur

Cas No.: 2748196-63-4

Größe Preis Lagerbestand Menge
500μg
64,00 $
Please Inquire
1mg
122,00 $
Please Inquire
5mg
510,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

P053 is an inhibitor of ceramide synthase 1 (CerS1; IC50s = 0.54 and 0.46 µM for human and mouse CerS1, respectively). It is selective for CerS1 over CerS2, CerS4, CerS5, and CerS6 (IC50s = 28.6, 17.2, 7.2, and 11.4 µM, respectively). P053 decreases the production of C18 ceramide from dihydrosphingosine in cortical neuron cultures in a concentration-dependent manner. It also lowers levels of C18 ceramide, C18 galactosylceramide, and C18:0 and 18:1 sphingomyelin species in HEK293 cells, when used at concentrations ranging from 30 to 300 nM, without inducing cell death. P053 (5 mg/kg) decreases endogenous C18 and C18:2/18:0 ceramide levels and increases C22:0 , C24:0 , and C24:1 ceramide levels in mouse skeletal muscle. It increases fatty acid oxidation in mouse skeletal muscle and inhibits triglyceride synthesis and increases in white adipose mass in a model of high-fat diet-induced obesity but does not affect insulin resistance.

Bewertungen

Review for P053

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for P053

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.